Stockscreener 앱 받기
3.13
0.97%
0.03
시간 외 거래:
3.12
-0.010
-0.32%
전일 마감가:
$3.10
열려 있는:
$3.05
하루 거래량:
303.25K
Relative Volume:
0.31
시가총액:
$97.15M
수익:
$80.97M
순이익/손실:
$-78.31M
주가수익비율:
-0.2824
EPS:
-11.0849
순현금흐름:
$-129.56M
1주 성능:
-11.08%
1개월 성능:
+6.83%
6개월 성능:
-15.63%
1년 성능:
+100.64%
1일 변동 폭
$3.0401
$3.1699
1주일 범위
$3.03
$3.515
52주 변동 폭
$1.325
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
명칭
Fortress Biotech Inc
전화
781-652-4500
주소
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
3.13 | 96.22M | 80.97M | -78.31M | -129.56M | -11.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-15 | 재개 | ROTH MKM | Buy |
| 2022-08-04 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-02 | 개시 | The Benchmark Company | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2018-02-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
| 2017-03-22 | 개시 | JMP Securities | Mkt Outperform |
| 2016-10-03 | 개시 | ROTH Capital | Buy |
모두보기
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
FBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Weekly Trades: Will Fortress Biotech Inc outperform during market ralliesTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Gap Down: Will Fortress Biotech Inc outperform during market ralliesNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Discipline and Rules-Based Execution in FBIOP Response - Stock Traders Daily
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M - Yahoo Finance
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Fortress Biotech’s (FBIO) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biot - GuruFocus
FBIO Eyes Future Growth Amid Financial Optimism - StocksToTrade
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy - Stocktwits
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biotech | FBIO Stock News - GuruFocus
Fortress Biotech Inc. Shares Soar After Promising New Developments - timothysykes.com
Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright - MarketBeat
Fortress Biotech: PRV Windfall and De-Risked Zycubo Economics Support Buy Rating and $17 Target - TipRanks
Fortress Biotech (FBIO) Sells Priority Review Voucher for $205 M - GuruFocus
Fortress Biotech Inc. Faces Stock Volatility Amid Strategic Adjustments - StocksToTrade
Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher - Quiver Quantitative
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics - GlobeNewswire
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Yahoo Finance
Strategic Acquisition Sends Fortress Biotech Stocks Soaring - timothysykes.com
Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - marketscreener.com
Cyprium Voucher Sale Bolsters Fortress Biotech Liquidity - TipRanks
Fortress Biotech Monetizes PRV for $205 Million; Amends Oaktree Credit Facility - TradingView
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Gains Recap: What is Fortress Biotech Incs revenue forecastEarnings Performance Report & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Insider Trends: Can SVIIU navigate macro headwindsJuly 2025 Selloffs & Weekly Market Pulse Updates - baoquankhu1.vn
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap - Seeking Alpha
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average – Here’s What Happened - Defense World
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Trade Report: Is Fortress Biotech Inc part of any ETFDividend Hike & Low Volatility Stock Recommendations - baoquankhu1.vn
MSN Money - MSN
Fortress Biotech amends credit agreement with Oaktree - MSN
Behavioral Patterns of FBIOP and Institutional Flows - Stock Traders Daily
What is Fortress Biotech Inc.’s book value per shareJuly 2025 Update & Reliable Intraday Trade Plans - mfd.ru
Does Fortress Biotech Inc. stock benefit from AI growthJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru
Does Fortress Biotech Inc. stock reflect fundamentals2025 Key Highlights & Expert Approved Trade Ideas - mfd.ru
Will Fortress Biotech Inc. stock recover faster than peers2025 Market Overview & Intraday High Probability Alerts - mfd.ru
Fortress Biotech Achieves Landmark FDA Approval for Rare Pediatric Disease Treatment () - aktiencheck.de
Wall Street Recap: How do insiders feel about Fortress Biotech IncDividend Hike & Trade Opportunity Analysis - baoquankhu1.vn
Fortress Biotech, Inc. (NASDAQ:FBIO) Might Not Be As Mispriced As It Looks After Plunging 28% - 富途牛牛
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower - simplywall.st
Fortress Biotech (NASDAQ:FBIO) Shares Jump Above Average Bulls Prepare For Follow Through - Kalkine Media
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving AverageWhat's Next? - MarketBeat
(FBIOP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Fortress Biotech (NASDAQ:FBIOP) Shares Down 4.7% – What’s Next? - Defense World
Fortress Biotech Leads High-Performing Stocks with 93.1% Return - Markets Mojo
Aug Technicals: Can Fortress Biotech Inc deliver alpha2025 Growth vs Value & Weekly Momentum Picks - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
Fortress Biotech Inc (FBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):